Gomisin A Alleviates Obesity by Regulating the Phenotypic Switch between White and Brown Adipocytes

Although gomisin A (GA) alleviates cancer and inflammation, its anti-obesity effect and the underlying mechanism have not yet been elucidated. Therefore, in this study, we aimed to elucidate the anti-obesity effects of GA by investigating the phenotypic changes involved in the browning and whitening of adipocytes. Here, obesity was induced to C57BL/6J mice using a high-fat diet (HFD). We administrated GA and checked weight changes for 12 weeks. We found that GA decreased the weight of weight gain, epididymal white adipose tissue (eWAT), and liver in the mice. In addition, the administration of GA elevated the levels of high-density lipoprotein (HDL)-cholesterol in the mice serum. Moreover, even after 12 weeks of treatment with GA, it did not cause any hepatic and renal toxicity. However, we found that GA induced the browning of eWAT and inhibited the whitening of brown adipose tissue. We further confirmed the anti-obesity mechanism of GA using 3T3-L1 cells, the human adipose mesenchymal stem cells (hAMSCs), and primary brown adipocytes (BAs) in vitroexperiments. We found that GA suppressed adipogenesis via the activation of AMP-activated protein kinase (AMPK). Furthermore, GA-induced browning by increasing the expression levels of uncoupling protein 1 (UCP1) in hAMSCs. The results of our study indicate that GA can inhibit weight gain by regulating the phenotypic changes involved in the browning and whitening of adipose tissues, which makes it a potential therapeutic agent for the treatment of obesity.

Automated summary

The study found that gomisin A (GA) can inhibit obesity by regulating phenotypic changes in adipose tissues through induction of browning and inhibition of whitening, resulting in decreased weight gain, epididymal white adipose tissue (eWAT) and liver weight, and increased levels of high-density lipoprotein (HDL) cholesterol in mice. GA suppresses adipogenesis by activating AMP-activated protein kinase (AMPK) and inducing browning by increasing the expression levels of uncoupling protein 1 (UCP1). These findings suggest that GA may be a potential therapeutic agent for obesity treatment.